基本信息
views: 5
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Toni Seppälä, born in Kouvola, Finland, is an accomplished gastroenterological surgeon and a tenure track professor of cancer research at the University of Tampere. He is also a research group leader at HUS Abdominal Center and the University of Helsinki. Seppälä completed his medical education and training at the University of Helsinki and further pursued a research fellowship at the esteemed Johns Hopkins University in the United States.
With a focus on colorectal cancer, Seppälä emphasizes the importance of early detection and national screening programs. He points to the United States as an example of how it's possible to reverse the incidence of colorectal cancer through strong commitment to screening in some states. Seppälä is also a proponent of targeting high-risk groups, such as those with unhealthy lifestyles, males, overweight individuals, smokers, and those with a family history of colorectal cancer, to improve patient prognosis.
In addition to his research on colorectal cancer, Seppälä has worked on Alzheimer's disease and Lynch Syndrome, a hereditary genetic defect predisposing carriers to cancer at a young age. He is particularly interested in precision medicine, using cutting-edge technologies like genomics, patient-derived organoids, and cell-free DNA to develop personalized cancer treatments.
Dr. Seppälä's groundbreaking research in organoids, three-dimensional cell structures grown from cancer cells, has the potential to significantly advance personalized cancer treatment. His research group isolates cells from tumor samples of patients with colorectal cancer and cultivates three-dimensional cell clusters in the laboratory. These organoids enable researchers to study specific patient tumor cells and their molecular-level characteristics, allowing for testing which treatments are most likely to be effective against cancer cells. While this method is still in the development stage, Dr. Seppälä believes it will become a practical tool in patient care in the future.
Dr. Seppälä also highlights the potential of liquid biopsies to provide detailed information about cancers by identifying pathological gene traces from tumor cells or extracellular tumor DNA in blood samples. This method is advanced enough to be introduced into clinical use in the near future and could potentially be used for population screening to detect early-stage cancers with a blood test.
Throughout his career, Dr. Seppälä has contributed to more than 100 articles, opinions, podcasts, and interviews, amassing over 3,800 citations. He has helped secure over 2.2 million euros in competitive research funding, demonstrating his dedication to cancer research and improving patient outcomes. Seppälä emphasizes the need for long-term, realistic research aimed at providing new tools and treatments for patients, acknowledging the significant challenge of funding for cancer research in Finland.
Research Interests
Papers共 145 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Hereditary Cancer in Clinical Practiceno. 1 (2024): 1-12
crossref(2024)
FRONTIERS IN ONCOLOGY (2024): 1333926-1333926
Meeri Kastinen, Päivi Sirniö, Hanna Elomaa, Ville K Äijälä, Henna Karjalainen, Vilja V Tapiainen,Vesa-Matti Pohjanen, Janette Kemppainen, Katja Sliashynskaya,Maarit Ahtiainen, Jukka Rintala, Sanna Meriläinen,
The American journal of surgical pathology (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn